Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tarsa Completes Phase III For Oral Calcitonin In Osteoporosis, Plans 2011 NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Initially, biotech will pursue a treatment indication but also has its recombinant oral formulation in Phase II for osteoporosis prevention.

You may also be interested in...

Financings Of The Fortnight Sees The Blooming Of New Life Sciences Funding Sources In The EU

Plus news on recent financing activity by Aastrom Biosciences, Tarsa Therapeutics, OncoGenex and Medivation.

Tarsa Raises $28 Million Series B to Support Regulatory Filings of Oral Calcitonin

Privately held firm believes oral calcitonin will enjoy several advantages over other osteoporosis therapies – ease of use compared to calcitonin nasal spray and safety compared to bisphosphonates.

Warner Chilcott’s Launch Of Atelvia Hits Headwinds

It has been a difficult year for Warner Chilcott PLC. But not an unexpected one.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts